Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS NYSE:ADCT OTCMKTS:NEVPF OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.87N/AN/AADCTADC Therapeutics$3.23-2.3%$2.62$1.05▼$4.13$318.86M1.89598,652 shs227,427 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$40.52-1.7%$40.13$34.10▼$44.31$258.43B0.452.49 million shs1.46 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ADCTADC Therapeutics+4.27%+18.10%-10.10%+171.19%+4.60%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%+180.00%RHHBYRoche+0.86%+1.93%+0.37%+8.19%+18.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AADCTADC Therapeutics1.595 of 5 stars3.52.00.00.00.00.80.6NEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ARHHBYRocheN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AADCTADC Therapeutics 3.00Buy$7.75140.31% UpsideNEVPFAbliva AB (publ) 0.00N/AN/AN/ARHHBYRoche 2.57Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest RHHBY, NEVPF, ACUS, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.004/28/2025RHHBYRocheHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/28/2025RHHBYRocheHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AADCTADC Therapeutics$70.84M4.52N/AN/A($2.10) per share-1.54NEVPFAbliva AB (publ)$10K1,128.43N/AN/A$0.02 per share1.40RHHBYRoche$68.73B3.76$3.27 per share12.40$6.44 per share6.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)NEVPFAbliva AB (publ)-$9.01MN/A0.00∞N/AN/A-117.92%-102.44%N/ARHHBYRoche$9.40BN/A0.0013.513.14N/AN/AN/A7/24/2025 (Estimated)Latest RHHBY, NEVPF, ACUS, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ADCTADC Therapeutics-$0.36N/AN/AN/A$17.82 millionN/A5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AADCTADC TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ARHHBYRoche$0.872.15%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AADCTADC TherapeuticsN/A4.464.16NEVPFAbliva AB (publ)N/A7.997.99RHHBYRoche0.851.481.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AADCTADC Therapeutics41.10%NEVPFAbliva AB (publ)N/ARHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ADCTADC Therapeutics5.40%NEVPFAbliva AB (publ)N/ARHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableNEVPFAbliva AB (publ)8403.01 millionN/ANot OptionableRHHBYRoche103,2496.38 billionN/ANot OptionableRHHBY, NEVPF, ACUS, and ADCT HeadlinesRecent News About These CompaniesPharma Companies Remain Calm Amid Fresh Tariff Threat by Trump4 hours ago | theglobeandmail.comSmart Money Going in Senior Health: Key Stocks in Elderly Care4 hours ago | zacks.comRoche Holding AG (OTCMKTS:RHHBY) Shares Bought by Moloney Securities Asset Management LLCJuly 9 at 9:45 AM | marketbeat.comRHHBY - Roche Holding AG ADR Sustainability - MorningstarJuly 8 at 3:18 PM | morningstar.comMRHHBY - Roche Holding AG ADR Chart - MorningstarJuly 3, 2025 | morningstar.comMChanges to the Roche Enlarged Corporate Executive CommitteeJune 30, 2025 | globenewswire.comRHHBY - Roche Holding AG ADR Trailing Returns - MorningstarJune 27, 2025 | morningstar.comMRHHBY Roche Holding AG - Seeking AlphaJune 27, 2025 | seekingalpha.comRHHBY - Roche Holding AG ADR Key Metrics - MorningstarJune 25, 2025 | morningstar.comMRHHBY - Roche Holding AG ADR Dividends - MorningstarJune 24, 2025 | morningstar.comMRoche Holding AG (RHHBY) Virtual Hematology Investor Conference TranscriptJune 23, 2025 | seekingalpha.comEarly data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia AJune 23, 2025 | uk.finance.yahoo.comAltrius Capital Management Inc Acquires 6,545 Shares of Roche Holding AG (OTCMKTS:RHHBY)June 22, 2025 | marketbeat.comRoche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphomaJune 20, 2025 | uk.finance.yahoo.comGenentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell LymphomaJune 20, 2025 | finance.yahoo.comRoche's Genentech reports positive results from lymphoma trialJune 20, 2025 | msn.comRoche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphomaJune 20, 2025 | globenewswire.comGenentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell LymphomaJune 20, 2025 | businesswire.comUBS Keeps Their Buy Rating on Roche Holding AG (RHHVF)June 18, 2025 | theglobeandmail.comRoche And Prothena: Why Moving On Makes SenseJune 18, 2025 | seekingalpha.comRoche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRHHBY, NEVPF, ACUS, and ADCT Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.ADC Therapeutics NYSE:ADCT$3.22 -0.08 (-2.27%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Abliva AB (publ) OTCMKTS:NEVPF$0.03 0.00 (0.00%) As of 07/9/2025Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Roche OTCMKTS:RHHBY$40.52 -0.70 (-1.70%) As of 02:22 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
